Bortezomib is an efficient agent in plasma cell leukemias.
about
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case reportPlasma cell leukemia.How I treat plasma cell leukemia.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.Targeting the proteasome as a therapeutic strategy against haematological malignancies.Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?Plasma cell leukemia: from biology to treatment.Primary Plasma Cell Leukemia: Identity Card 2016.Potential Use of Flavopiridol in Treatment of Chronic Diseases.Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience
P2860
Q21198810-E62AA1E6-271F-4EA1-927F-1290436570C6Q33393995-87230525-9E42-4B17-B651-7613E058FF35Q33402555-4A81E1D0-5F76-44B8-B545-584E9F1601D8Q33807542-18400CAE-E420-48DE-ABFB-1E9391411B21Q33956990-CB9B31DD-FFC1-4600-BC27-A14823BC88CDQ34371798-6701A93F-E987-4BCD-B1D8-7158DAEFAA5FQ35742685-8D85B8B2-509C-461C-993D-441546EA3170Q36376437-A1672C42-020D-4708-8588-9CC31DFB780BQ37723147-750242C3-575A-46DE-A4E3-41FFA14C66F8Q38380625-AE48C57E-5108-4E68-9FEB-8C299E7658E1Q38781794-28976E8E-0057-4F7E-83CF-0F4189412663Q38988581-3A4B00D6-C2DE-4B26-AD04-54CFC92B033FQ39475750-5E36E0A1-7173-4D24-A349-945F0B2ECD31Q44559311-DF37C7D3-FD53-4FBB-99E9-AF625B77E7EAQ44962191-CE836CE6-D289-4483-BC43-4D618B1B32A3Q46817722-CA406551-62AF-463D-A0F6-069EBDF7693BQ48283707-04C41F90-DD33-4BEB-9CB2-1856BE3F19B6Q58051878-1E7F0640-E39B-478B-95D1-8020D68D07EA
P2860
Bortezomib is an efficient agent in plasma cell leukemias.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Bortezomib is an efficient agent in plasma cell leukemias.
@ast
Bortezomib is an efficient agent in plasma cell leukemias.
@en
type
label
Bortezomib is an efficient agent in plasma cell leukemias.
@ast
Bortezomib is an efficient agent in plasma cell leukemias.
@en
prefLabel
Bortezomib is an efficient agent in plasma cell leukemias.
@ast
Bortezomib is an efficient agent in plasma cell leukemias.
@en
P2093
P2860
P356
P1476
Bortezomib is an efficient agent in plasma cell leukemias.
@en
P2093
Adrián Alegre
Atanasio Pandiella
Beatriz Aguado
David Schenkein
Gema Mateo
Jesús F San Miguel
Joan Bladé
P2860
P304
P356
10.1002/IJC.20793
P577
2005-04-01T00:00:00Z